TY - JOUR
T1 - Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
AU - Ferguson, Sherise D.
AU - Fomchenko, Elena I.
AU - Guerrieri, Renato A.
AU - Glitza Oliva, Isabella C.
N1 - Publisher Copyright:
Copyright © 2022 Ferguson, Fomchenko, Guerrieri and Glitza Oliva.
PY - 2022/1/12
Y1 - 2022/1/12
N2 - Leptomeningeal disease (LMD) is a devastating category of CNS metastasis with a very poor prognosis and limited treatment options. With maximal aggressive therapy, survival times remain short and, without treatment, prognosis is measured in weeks. Both LMD diagnosis and treatment are challenging topics within neuro-oncology. In this review, we discuss the advances in LMD diagnosis with a focus on the role of circulating tumor DNA (ctDNA) and discuss the role of targeted and immunotherapy in LMD treatment.
AB - Leptomeningeal disease (LMD) is a devastating category of CNS metastasis with a very poor prognosis and limited treatment options. With maximal aggressive therapy, survival times remain short and, without treatment, prognosis is measured in weeks. Both LMD diagnosis and treatment are challenging topics within neuro-oncology. In this review, we discuss the advances in LMD diagnosis with a focus on the role of circulating tumor DNA (ctDNA) and discuss the role of targeted and immunotherapy in LMD treatment.
KW - ctDNA = circulating tumor DNA
KW - immunothearpy
KW - intrathecal therapy
KW - leptomeningeal disease
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85123411609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123411609&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.800053
DO - 10.3389/fonc.2021.800053
M3 - Review article
C2 - 35096602
AN - SCOPUS:85123411609
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 800053
ER -